Q-omics provides the consensus-scored ZNF646 profile across patient tissues and cancer cell-line models. ZNF646 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF646 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, ZNF646 RNA expression shows 20,387 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, and ACC as cancer lineages where ZNF646 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF646 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF646 survival associations across molecular data types. ZNF646 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (11) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF646 RNA expression–survival associations across cancer types. High ZNF646 expression shows unfavorable associations in LIHC, ACC and LUSC, but favorable associations in HNSC, KIRC and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF646 RNA expression.
This table summarizes ZNF646 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF646. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF646 shows higher tumor expression in HNSC, KIRP, KIRC, LIHC, STAD and BRCA. The HNSC box plot shows higher ZNF646 RNA expression in tumor versus normal tissue (log2 FC = +0.974, t-test p < 0.001).
This table shows molecular features associated with ZNF646 in patient tissues and cancer cell lines. In patient samples, ZNF646 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF646 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
